IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 15.5% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 11,386 shares of the medical research company’s stock after selling 2,081 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in IQVIA were worth $2,407,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Jennison Associates LLC increased its holdings in IQVIA by 7.3% in the 1st quarter. Jennison Associates LLC now owns 140,914 shares of the medical research company’s stock valued at $35,636,000 after purchasing an additional 9,578 shares during the last quarter. Cadian Capital Management LP purchased a new stake in shares of IQVIA in the 4th quarter valued at $70,108,000. Nomura Holdings Inc. acquired a new position in IQVIA during the 4th quarter worth about $857,000. PGGM Investments boosted its holdings in IQVIA by 55.8% during the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after acquiring an additional 4,326 shares during the period. Finally, Fiduciary Alliance LLC acquired a new position in IQVIA in the 1st quarter valued at about $1,864,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

Shares of IQVIA stock opened at $239.98 on Wednesday. The firm has a market capitalization of $43.75 billion, a P/E ratio of 32.78, a P/E/G ratio of 2.24 and a beta of 1.49. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73. The firm’s 50 day moving average is $239.12 and its two-hundred day moving average is $234.12.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping the consensus estimate of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The firm had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. During the same period last year, the business earned $2.22 EPS. IQVIA’s revenue for the quarter was up 2.3% compared to the same quarter last year. Research analysts forecast that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

Analyst Ratings Changes

IQV has been the topic of several research reports. The Goldman Sachs Group began coverage on shares of IQVIA in a research report on Thursday, June 6th. They set a “buy” rating and a $270.00 price target on the stock. JPMorgan Chase & Co. boosted their price target on shares of IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a research note on Monday, August 5th. Jefferies Financial Group cut IQVIA from a “buy” rating to a “hold” rating and reduced their price objective for the company from $266.00 to $242.00 in a research note on Wednesday, July 24th. Truist Financial boosted their target price on IQVIA from $292.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Finally, Barclays increased their price target on IQVIA from $255.00 to $275.00 and gave the company an “overweight” rating in a research report on Tuesday, July 23rd. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $266.67.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.